Dipna Pharmachem Ltd Stock Price Today (NSE: DPL)
Fundamental Score
Dipna Pharmachem Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dipna Pharmachem Ltd share price today is ₹6.99, down 2.37% on NSE/BSE as of 19 June 2026. Dipna Pharmachem Ltd (DPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹40.40 (Cr). The 52-week high for DPL share price is ₹25.66 and the 52-week low is ₹6.66. At a P/E ratio of 19.71x, DPL is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 2.55% and a debt-to-equity ratio of 0.23.
Dipna Pharmachem Ltd Share Price Chart — NSE/BSE Historical Performance
Dipna Pharmachem Ltd share price chart: -14.55% return over the past month. 52-week high ₹25.66, 52-week low ₹6.66.
Dipna Pharmachem Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹7.00 | ₹7.15 | ₹6.66 | ₹6.99 | 57.00K (Cr) | |
| ₹7.33 | ₹7.33 | ₹7.00 | ₹7.16 | 60.00K (Cr) | |
| ₹7.25 | ₹7.40 | ₹7.25 | ₹7.33 | 6.00K (Cr) | |
| ₹7.81 | ₹7.81 | ₹7.04 | ₹7.75 | 42.00K (Cr) | |
| ₹7.36 | ₹7.59 | ₹6.82 | ₹7.50 | 1.86L (Cr) | |
| ₹7.98 | ₹7.98 | ₹7.47 | ₹7.50 | 15.00K (Cr) | |
| ₹7.60 | ₹7.60 | ₹7.46 | ₹7.52 | 57.00K (Cr) | |
| ₹7.24 | ₹8.05 | ₹7.24 | ₹8.05 | 12.00K (Cr) | |
| ₹8.14 | ₹8.22 | ₹7.42 | ₹8.22 | 48.00K (Cr) | |
| ₹8.01 | ₹8.01 | ₹7.41 | ₹7.41 | 36.00K (Cr) |
Dipna Pharmachem Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹7.33 | ₹7.33 | ₹6.66 | ₹6.99 | -4.64% | |
| ₹8.00 | ₹8.74 | ₹6.82 | ₹7.33 | -8.38% | |
| ₹8.80 | ₹10.70 | ₹7.25 | ₹7.94 | -9.77% | |
| ₹8.95 | ₹10.64 | ₹7.45 | ₹8.02 | -10.39% | |
| ₹14.00 | ₹15.00 | ₹9.00 | ₹9.04 | -35.43% | |
| ₹17.25 | ₹17.25 | ₹11.23 | ₹14.39 | -16.58% | |
| ₹17.00 | ₹17.45 | ₹12.92 | ₹16.90 | -0.59% | |
| ₹19.63 | ₹19.92 | ₹13.96 | ₹16.66 | -15.13% | |
| ₹20.00 | ₹25.00 | ₹19.00 | ₹19.63 | -1.85% | |
| ₹19.95 | ₹23.00 | ₹18.72 | ₹20.07 | +0.60% | |
| ₹22.76 | ₹23.47 | ₹18.45 | ₹19.00 | -16.52% | |
| ₹21.59 | ₹25.66 | ₹21.59 | ₹23.30 | +7.92% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Dipna Pharmachem is a micro-cap gamble, not an investment.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Dipna Pharmachem's stock price has experienced significant movement, prompting the exchange to seek clarification from the company on multiple occasions. The exchange sought clarification on February 23, 2026, January 13, 2026 and April 7, 2026 regarding the price movement. The company allotted 22,44,000 equity shares following the conversion of warrants to non-promoter entities.
CORE STORY (THE REAL GAME)
Micro-cap pharma play, vulnerable to price swings and speculative trading. Not a long-term value creator.
- Significant price volatility
- Equity dilution from warrant conversion
- Overall tailwinds in the Indian pharma sector
- Significant order wins
- Successful backward integration into API manufacturing
- Improved financial performance
- Low promoter holding: 9.98%
- Exchange seeking clarification on price movement
- Micro-cap with inherent liquidity risk
No FII or DII interest. Promoter holding is low and unchanged.
Indian pharmaceutical industry projected to reach $130 billion by 2030 - a potential tailwind, but DPL needs to execute.
No. Free Cash Flow 5Y: ₹-35.27 Cr.
Near-term outlook is highly uncertain. DPL needs to demonstrate consistent profitability and secure significant orders to justify its valuation. Avoid until clear signs of a turnaround emerge.
Primary Thesis Risk
Illiquidity and governance concerns could lead to a complete collapse in value.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dipna Pharmachem Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dipna Pharmachem Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DPL across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 19.71 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (314.71%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (32.54% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (74.47% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.23)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (2.55%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.64%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.46%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-18.85%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Earnings Growth (-41.72% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Weak Interest Coverage (2.43x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-35.27 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (9.98%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Dipna Pharmachem Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Dipna Pharmachem Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Dipna Pharmachem LtdDipna Pharmache...Selected✓ DPL • 543594 | 39.4/100 | ₹6.99₹7 | ₹40.40₹40.40 | 19.71Average 19.7 Average | 2.55%Poor 2.55% Poor | 6.64%Poor 6.64% Poor | 0.23Excellent 0.2 Excellent | 74.47%Excellent 74.47% Excellent | 32.54%Excellent 32.54% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Dipna Pharmachem Ltd PE Ratio History
Historical price-to-earnings ratio for DPL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.90 | ₹14.41 | 16x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dipna Pharmachem Ltd Quarterly Performance
Latest quarterly metrics for DPL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-18.85%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
314.71%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
32.54%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
74.47%
Compounded annual net profit growth over 5 years
Dipna Pharmachem Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for DPL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Dipna Pharmachem Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Dipna Pharmachem Ltd (DPL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Dipna Pharmachem Ltd
About DPL (Dipna Pharmachem Ltd)
Dipna Pharmachem Ltd is a dynamic and innovative pharmaceutical company that acts as a vital bridge in the complex global supply chain. Situated in the heart of Ahmedabad, India, D...PL specializes in the procurement, distribution, and export of an extensive range of pharmaceutical necessities. From the foundational building blocks of drug development to the crucial components that ensure formulation stability, DPL provides a comprehensive portfolio tailored to meet the diverse needs of the pharmaceutical industry. The company prides itself on a dedication to sourcing high-quality materials, fostering strong relationships with both suppliers and customers, and maintaining a meticulous approach to regulatory compliance, solidifying its position as a trusted partner in the ever-evolving landscape of pharmaceutical manufacturing. At the core of Dipna Pharmachem's operations lies a robust commitment to providing a diverse selection of essential pharmaceutical ingredients. DPL meticulously sources and supplies active pharmaceutical ingredients (APIs) that are the core of many medications. Furthermore, the company offers an array of crucial industrial chemicals, meticulously selected excipients that serve to enhance drug delivery and stability, high-purity solvents that facilitate critical chemical reactions, complex formulations that need specific elements and unique intermediates that allow for innovation in various pharmaceutical synthesis pathways. This multifaceted product offering enables DPL to cater to a broad spectrum of clients within the pharmaceutical sector, ranging from research institutions to large-scale manufacturing facilities, creating a wide area of clientele and need. Founded in 2011, Dipna Pharmachem Ltd has rapidly established itself as a reliable and agile player in the Indian pharmaceutical market. Driven by a customer-centric philosophy, DPL strives to exceed expectations through responsive service, competitive pricing, and a commitment to delivering superior products. The company leverages its strategic location in Ahmedabad to efficiently manage its import, trade, and export operations, ensuring timely delivery to clients both domestically and internationally. With a focus on continuous improvement and adaptation to the evolving needs of the pharmaceutical industry, Dipna Pharmachem Ltd is poised to continue its growth trajectory and solidify its position as a trusted partner for pharmaceutical companies worldwide.
Company Details
Key Leadership
Latest News
DPL Share Price: Frequently Asked Questions
What is the current share price of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd (DPL) trades at ₹6.99 on NSE and BSE. Market cap ₹40.40 (Cr). Educational data only.
What is the P/E ratio of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd has a P/E of 19.71x vs industry average 31.77x.
What is the Bull Run score for Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd has a Bull Run score of 39.4/100 based on 25+ financial parameters.
Does Dipna Pharmachem Ltd pay dividends?
Dipna Pharmachem Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd has ROE of 2.55%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd has debt-to-equity of 0.23.
Is Dipna Pharmachem Ltd a good investment?
Bull Run gives Dipna Pharmachem Ltd a score of 39.4/100. This is not investment advice — consult a SEBI-registered advisor.